Recent News

• 06.13.2025 - Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions
• 06.13.2025 - Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions
• 06.04.2025 - Jefferies Global Healthcare Conference
• 06.04.2025 - Jefferies Global Healthcare Conference
• 05.20.2025 - H.C. Wainwright 3rd Annual BioConnect Investor Conference
• 05.20.2025 - H.C. Wainwright 3rd Annual BioConnect Investor Conference
• 05.19.2025 - Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
• 05.19.2025 - Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
• 05.14.2025 - Altimmune to Participate at Two Upcoming Investor Conferences
• 05.14.2025 - Altimmune to Participate at Two Upcoming Investor Conferences

Recent Filings

• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.13.2025 - 8-K Current report